BioAtla公司宣布,在完成特殊目的载体(SPV)交易后,该公司将继续持有其候选药物Oz-V在所有实体瘤适应症领域65%的所有权权益。这一安排巩固了BioAtla对该资产的主要控制权,并凸显了公司对其开发前景的信心。
BioAtla公司宣布,在完成特殊目的载体(SPV)交易后,该公司将继续持有其候选药物Oz-V在所有实体瘤适应症领域65%的所有权权益。这一安排巩固了BioAtla对该资产的主要控制权,并凸显了公司对其开发前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.